Report DMCA The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic
* Please fill this form as much details as possible, we will respond to your request within 2 to 3 business days.
* Please fill this form as much details as possible, we will respond to your request within 2 to 3 business days.